Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

Research output: Contribution to journalComment/Letter to the editorAcademic

Original languageEnglish
Pages (from-to)822-823
JournalMultiple Sclerosis Journal
Volume24
Issue number6
DOIs
Publication statusPublished - 2018

Cite this